GB9120306D0
(en)
|
1991-09-24 |
1991-11-06 |
Graham Herbert K |
Method and compositions for the treatment of cerebral palsy
|
US20040126396A1
(en)
*
|
1993-12-28 |
2004-07-01 |
Allergan, Inc. |
Botulinum toxin treatment for strabismus
|
US6974578B1
(en)
*
|
1993-12-28 |
2005-12-13 |
Allergan, Inc. |
Method for treating secretions and glands using botulinum toxin
|
US8187612B2
(en)
*
|
1993-12-28 |
2012-05-29 |
Allergan, Inc. |
Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
|
US8557256B2
(en)
*
|
1993-12-28 |
2013-10-15 |
Allergan, Inc. |
Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
|
US9415222B2
(en)
|
1998-08-05 |
2016-08-16 |
Cyberonics, Inc. |
Monitoring an epilepsy disease state with a supervisory module
|
US7747325B2
(en)
|
1998-08-05 |
2010-06-29 |
Neurovista Corporation |
Systems and methods for monitoring a patient's neurological disease state
|
US8762065B2
(en)
|
1998-08-05 |
2014-06-24 |
Cyberonics, Inc. |
Closed-loop feedback-driven neuromodulation
|
US9320900B2
(en)
|
1998-08-05 |
2016-04-26 |
Cyberonics, Inc. |
Methods and systems for determining subject-specific parameters for a neuromodulation therapy
|
US9042988B2
(en)
|
1998-08-05 |
2015-05-26 |
Cyberonics, Inc. |
Closed-loop vagus nerve stimulation
|
US7209787B2
(en)
|
1998-08-05 |
2007-04-24 |
Bioneuronics Corporation |
Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
|
US9375573B2
(en)
|
1998-08-05 |
2016-06-28 |
Cyberonics, Inc. |
Systems and methods for monitoring a patient's neurological disease state
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6306403B1
(en)
*
|
2000-06-14 |
2001-10-23 |
Allergan Sales, Inc. |
Method for treating parkinson's disease with a botulinum toxin
|
EP1365800B1
(de)
*
|
2000-06-28 |
2013-03-06 |
Ira Sanders |
Methoden zur verwendung von tetanustoxin zur therapeutischen anwendung bei lebewesen (säugetieren)
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
US7491799B2
(en)
*
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
US20040219619A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Ester Fernandez-Salas |
Methods of identifying compounds that alter toxin persistence and/or protease activity
|
US7691983B2
(en)
*
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
AU2002236495B2
(en)
|
2000-11-29 |
2006-05-11 |
Allergan, Inc. |
Intraocular implants for preventing transplant rejection in the eye
|
US7749539B2
(en)
*
|
2000-11-30 |
2010-07-06 |
Efrat Biopolymers Ltd. |
Polymeric formulations for drug delivery
|
JP4707254B2
(ja)
*
|
2001-04-24 |
2011-06-22 |
クミアイ化学工業株式会社 |
粒状組成物及びその製造方法
|
US6984375B2
(en)
*
|
2001-08-03 |
2006-01-10 |
Allergan, Inc. |
Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
|
US20030105409A1
(en)
|
2001-11-14 |
2003-06-05 |
Donoghue John Philip |
Neurological signal decoding
|
EA006739B1
(ru)
*
|
2001-11-15 |
2006-04-28 |
Майкроу Элджи Корпорейшн |
Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
|
US20050163809A1
(en)
*
|
2002-03-29 |
2005-07-28 |
Ryuji Kaji |
Remedy for hypermyotonia
|
US20040058313A1
(en)
*
|
2002-04-24 |
2004-03-25 |
Abreu Marcio Marc |
Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
|
US6921538B2
(en)
*
|
2002-05-10 |
2005-07-26 |
Allergan, Inc. |
Therapeutic treatments for neuropsychiatric disorders
|
US7691394B2
(en)
*
|
2002-05-28 |
2010-04-06 |
Botulinum Toxin Research Associates, Inc. |
High-potency botulinum toxin formulations
|
AU2003239957A1
(en)
*
|
2002-06-04 |
2003-12-19 |
Cyberkinetics, Inc. |
Optically-connected implants and related systems and methods of use
|
US7212851B2
(en)
*
|
2002-10-24 |
2007-05-01 |
Brown University Research Foundation |
Microstructured arrays for cortex interaction and related methods of manufacture and use
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US7238357B2
(en)
*
|
2002-11-05 |
2007-07-03 |
Allergan, Inc. |
Methods for treating ulcers and gastroesophageal reflux disease
|
MXPA05009425A
(es)
*
|
2003-03-06 |
2006-02-10 |
Botulinum Toxin Res Ass Inc |
Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
|
US7670608B2
(en)
*
|
2003-03-06 |
2010-03-02 |
Botulinum Toxin Research Associates, Inc. |
Selection of patients with increased responsiveness to botulinum toxin
|
EP1617862B1
(de)
*
|
2003-04-25 |
2012-12-05 |
Allergan, Inc. |
Botulinum Neurotoxin zur Behandlung von "obsessive compulsive behaviors" Symptomen
|
US7390496B2
(en)
|
2003-04-25 |
2008-06-24 |
Allergan, Inc. |
Therapeutic treatments for repetitive hand washing
|
US7393538B2
(en)
*
|
2003-04-25 |
2008-07-01 |
Ackerman Alan H |
Clostridial toxin treatment for dermatillomania
|
US7393537B2
(en)
|
2003-04-25 |
2008-07-01 |
Allergan, Inc. |
Botulinum toxin for treatment of obsessive compulsive finger biting disorder
|
US7422753B2
(en)
*
|
2003-04-25 |
2008-09-09 |
Allergan, Inc. |
Methods for treating trichotillomania
|
US7396535B2
(en)
*
|
2003-04-25 |
2008-07-08 |
Ackerman Alan H |
Therapy for obsessive compulsive head banging
|
AU2011203509B2
(en)
*
|
2003-04-25 |
2014-02-06 |
Allergan, Inc. |
Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
|
US6838434B2
(en)
*
|
2003-05-02 |
2005-01-04 |
Allergan, Inc. |
Methods for treating sinus headache
|
US20040226556A1
(en)
|
2003-05-13 |
2004-11-18 |
Deem Mark E. |
Apparatus for treating asthma using neurotoxin
|
US7220422B2
(en)
|
2003-05-20 |
2007-05-22 |
Allergan, Inc. |
Methods and compositions for treating eye disorders
|
WO2004111074A2
(en)
*
|
2003-05-30 |
2004-12-23 |
The Cleveland Clinic Foundation |
In vivo production of a clostridial neurotoxin light chain peptide
|
US20040253274A1
(en)
*
|
2003-06-11 |
2004-12-16 |
Allergan, Inc. |
Use of a clostridial toxin to reduce appetite
|
US20050013850A1
(en)
*
|
2003-07-15 |
2005-01-20 |
Caers Jan K. |
Device to assist hyperhydrosis therapy
|
US20050214413A1
(en)
*
|
2003-08-26 |
2005-09-29 |
Mannatech, Inc. |
Methods and compositions for modified release of nutritional supplements
|
US20090076391A1
(en)
*
|
2003-10-15 |
2009-03-19 |
Der-Yang Tien |
Method and system for leading macromolecule substances into living target cells
|
TWI243696B
(en)
*
|
2003-10-15 |
2005-11-21 |
Der-Yang Tien |
System for introducing macromolecule substance into living target cell
|
US20110071381A1
(en)
*
|
2003-10-15 |
2011-03-24 |
Robert Tien |
Method and system for leading macromolecule substances into living target cells
|
US8617572B2
(en)
*
|
2003-10-29 |
2013-12-31 |
Allergan, Inc. |
Botulinum toxin treatments of depression
|
US8609113B2
(en)
|
2003-10-29 |
2013-12-17 |
Allergan, Inc. |
Botulinum toxin treatments of depression
|
US8734810B2
(en)
*
|
2003-10-29 |
2014-05-27 |
Allergan, Inc. |
Botulinum toxin treatments of neurological and neuropsychiatric disorders
|
US8609112B2
(en)
|
2003-10-29 |
2013-12-17 |
Allergan, Inc. |
Botulinum toxin treatments of depression
|
US20050143589A1
(en)
*
|
2003-11-09 |
2005-06-30 |
Donoghue John P. |
Calibration systems and methods for neural interface devices
|
US7172764B2
(en)
*
|
2003-11-17 |
2007-02-06 |
Allergan, Inc. |
Rescue agents for treating botulinum toxin intoxications
|
US20050113744A1
(en)
*
|
2003-11-21 |
2005-05-26 |
Cyberkinetics, Inc. |
Agent delivery systems and related methods under control of biological electrical signals
|
US7751877B2
(en)
*
|
2003-11-25 |
2010-07-06 |
Braingate Co., Llc |
Neural interface system with embedded id
|
US20050129677A1
(en)
*
|
2003-12-10 |
2005-06-16 |
Shengwen Li |
Lipid rafts and clostridial toxins
|
US7647097B2
(en)
*
|
2003-12-29 |
2010-01-12 |
Braingate Co., Llc |
Transcutaneous implant
|
US20050148935A1
(en)
*
|
2003-12-29 |
2005-07-07 |
Rozalina Dimitrova |
Botulinum toxin injection guide
|
US20050203366A1
(en)
*
|
2004-03-12 |
2005-09-15 |
Donoghue John P. |
Neurological event monitoring and therapy systems and related methods
|
WO2005110275A1
(en)
*
|
2004-05-07 |
2005-11-24 |
Phytotox Limited |
Methods of treating wounds with gonyautoxins
|
JP2007538010A
(ja)
*
|
2004-05-07 |
2007-12-27 |
ファイトトックス リミテッド |
フィコトキシンの経皮投与
|
US7811584B2
(en)
*
|
2004-06-30 |
2010-10-12 |
Allergan, Inc. |
Multivalent clostridial toxins
|
US7514088B2
(en)
*
|
2005-03-15 |
2009-04-07 |
Allergan, Inc. |
Multivalent Clostridial toxin derivatives and methods of their use
|
CA2572865C
(en)
|
2004-07-09 |
2017-07-25 |
Robert Sabin |
Compositions and methods of use for treatment of mammalian diseases
|
US8173797B2
(en)
*
|
2004-07-21 |
2012-05-08 |
Cornell Research Foundation, Inc. |
Therapeutic compounds derived from spider venom and their method of use
|
US20060024794A1
(en)
*
|
2004-07-30 |
2006-02-02 |
Shengwen Li |
Novel methods for production of di-chain botulinum toxin
|
US20060049957A1
(en)
*
|
2004-08-13 |
2006-03-09 |
Surgenor Timothy R |
Biological interface systems with controlled device selector and related methods
|
JP5089388B2
(ja)
|
2004-09-01 |
2012-12-05 |
アラーガン、インコーポレイテッド |
分解可能なクロストリジウム毒素
|
WO2006034305A2
(en)
*
|
2004-09-21 |
2006-03-30 |
University Of Florida Research Foundation, Inc. |
Multiple lead method for deep brain stimulation
|
US20060073208A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Allergan, Inc. |
Cosmetic neurotoxin compositions and methods
|
EP1827207A2
(de)
*
|
2004-10-04 |
2007-09-05 |
Cyberkinetics Neurotechnology Systems, Inc. |
Biologisches schnittstellensystem
|
US8000795B2
(en)
*
|
2004-12-17 |
2011-08-16 |
Lozano Andres M |
Cognitive function within a human brain
|
WO2006071813A2
(en)
*
|
2004-12-23 |
2006-07-06 |
Massachusetts Institute Of Technology |
Disposable medical supplies from hydrolytically biodegradable plastics
|
US8095209B2
(en)
*
|
2005-01-06 |
2012-01-10 |
Braingate Co., Llc |
Biological interface system with gated control signal
|
US7901368B2
(en)
|
2005-01-06 |
2011-03-08 |
Braingate Co., Llc |
Neurally controlled patient ambulation system
|
US20060253166A1
(en)
*
|
2005-01-06 |
2006-11-09 |
Flaherty J C |
Patient training routine for biological interface system
|
WO2006076175A2
(en)
*
|
2005-01-10 |
2006-07-20 |
Cyberkinetics Neurotechnology Systems, Inc. |
Biological interface system with patient training apparatus
|
US20060189899A1
(en)
*
|
2005-01-10 |
2006-08-24 |
Flaherty J Christopher |
Joint movement apparatus
|
US7881780B2
(en)
*
|
2005-01-18 |
2011-02-01 |
Braingate Co., Llc |
Biological interface system with thresholded configuration
|
US7158607B2
(en)
*
|
2005-02-10 |
2007-01-02 |
Brookhaven Science Associates, Llc |
Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams
|
US7194063B2
(en)
*
|
2005-02-10 |
2007-03-20 |
Brookhaven Science Associates, Llc |
Methods for implementing microbeam radiation therapy
|
US20080192892A1
(en)
*
|
2005-02-10 |
2008-08-14 |
Brookhaven Science Associates |
Methods for Implementing Microbeam Radiation Therapy
|
MX2007010673A
(es)
*
|
2005-03-03 |
2008-04-07 |
Revance Therapeutics Inc |
Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
|
CA2601577A1
(en)
|
2005-03-15 |
2006-09-21 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
US9511210B2
(en)
|
2006-05-19 |
2016-12-06 |
The Foundry, Llc |
Apparatus for toxin delivery to the nasal cavity
|
US10052465B2
(en)
|
2005-07-22 |
2018-08-21 |
The Foundry, Llc |
Methods and systems for toxin delivery to the nasal cavity
|
US7608275B2
(en)
|
2005-07-22 |
2009-10-27 |
The Foundry, Llc |
Systems and methods for delivery of a therapeutic agent
|
US7910116B2
(en)
*
|
2005-08-24 |
2011-03-22 |
Allergan, Inc. |
Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
|
US20070106143A1
(en)
*
|
2005-11-08 |
2007-05-10 |
Flaherty J C |
Electrode arrays and related methods
|
US20070156126A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Flaherty J C |
Medical device insertion system and related methods
|
US8868172B2
(en)
|
2005-12-28 |
2014-10-21 |
Cyberonics, Inc. |
Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
|
US8725243B2
(en)
|
2005-12-28 |
2014-05-13 |
Cyberonics, Inc. |
Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
US20070218084A1
(en)
*
|
2005-12-30 |
2007-09-20 |
Fondazione Pierfranco E Luisa Mariani- Onlus |
Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
|
US7794386B2
(en)
|
2006-03-15 |
2010-09-14 |
Allergan, Inc. |
Methods for facilitating weight loss
|
US7811586B2
(en)
*
|
2006-05-02 |
2010-10-12 |
Allergan, Inc. |
Methods for alleviating testicular pain
|
US7998128B2
(en)
*
|
2006-05-15 |
2011-08-16 |
Therataxis, LLC. |
Active delivery and flow redirection: novel devices and method of delivery of materials to patients
|
US20080021341A1
(en)
|
2006-06-23 |
2008-01-24 |
Neurovista Corporation A Delware Corporation |
Methods and Systems for Facilitating Clinical Trials
|
US20080092910A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Allergan, Inc. |
Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
|
US20080113051A1
(en)
*
|
2006-11-13 |
2008-05-15 |
Allergan, Inc. |
Methods for alleviating tattoo pain
|
US8295934B2
(en)
|
2006-11-14 |
2012-10-23 |
Neurovista Corporation |
Systems and methods of reducing artifact in neurological stimulation systems
|
EP2126785A2
(de)
|
2007-01-25 |
2009-12-02 |
NeuroVista Corporation |
Systeme und verfahren zur identifikation des kontra-iktalen zustands eines patienten
|
US8374673B2
(en)
|
2007-01-25 |
2013-02-12 |
Warsaw Orthopedic, Inc. |
Integrated surgical navigational and neuromonitoring system having automated surgical assistance and control
|
US7987001B2
(en)
|
2007-01-25 |
2011-07-26 |
Warsaw Orthopedic, Inc. |
Surgical navigational and neuromonitoring instrument
|
WO2008092133A2
(en)
|
2007-01-25 |
2008-07-31 |
Neurovista Corporation |
Methods and systems for measuring a subject's susceptibility to a seizure
|
US7747551B2
(en)
*
|
2007-02-21 |
2010-06-29 |
Neurovista Corporation |
Reduction of classification error rates and monitoring system using an artificial class
|
US8036736B2
(en)
|
2007-03-21 |
2011-10-11 |
Neuro Vista Corporation |
Implantable systems and methods for identifying a contra-ictal condition in a subject
|
US20090005756A1
(en)
*
|
2007-06-29 |
2009-01-01 |
Boston Scientific Neuromodulation Corporation |
Methods and Systems of Treating Strabismus
|
TW200903724A
(en)
*
|
2007-07-09 |
2009-01-16 |
Ind Tech Res Inst |
Phase change memory device and method of fabricating the same
|
US9788744B2
(en)
|
2007-07-27 |
2017-10-17 |
Cyberonics, Inc. |
Systems for monitoring brain activity and patient advisory device
|
US9259591B2
(en)
|
2007-12-28 |
2016-02-16 |
Cyberonics, Inc. |
Housing for an implantable medical device
|
US20090171168A1
(en)
|
2007-12-28 |
2009-07-02 |
Leyde Kent W |
Systems and Method for Recording Clinical Manifestations of a Seizure
|
US8483831B1
(en)
|
2008-02-15 |
2013-07-09 |
Holaira, Inc. |
System and method for bronchial dilation
|
US8470337B2
(en)
*
|
2008-03-13 |
2013-06-25 |
Allergan, Inc. |
Therapeutic treatments using botulinum neurotoxin
|
CA2723806C
(en)
|
2008-05-09 |
2022-05-31 |
Innovative Pulmonary Solutions, Inc. |
Systems, assemblies, and methods for treating a bronchial tree
|
WO2010013495A1
(ja)
*
|
2008-07-31 |
2010-02-04 |
財団法人化学及血清療法研究所 |
高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
|
US8270698B2
(en)
|
2008-09-24 |
2012-09-18 |
Merge Healthcare Incorporated |
Anterior commissure and posterior commissure segmentation system and method
|
US20100124559A1
(en)
*
|
2008-11-20 |
2010-05-20 |
Allergan, Inc. |
Early Treatment and Prevention of Increased Muscle Tonicity
|
EP2364168A1
(de)
|
2008-12-04 |
2011-09-14 |
Botulinum Toxin Research Associates, Inc. |
Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren
|
US8849390B2
(en)
|
2008-12-29 |
2014-09-30 |
Cyberonics, Inc. |
Processing for multi-channel signals
|
US8588933B2
(en)
|
2009-01-09 |
2013-11-19 |
Cyberonics, Inc. |
Medical lead termination sleeve for implantable medical devices
|
EP2246065A1
(de)
|
2009-04-29 |
2010-11-03 |
Merz Pharma GmbH & Co. KGaA |
Intrastriatale Botulintoxin-Therapie
|
US8786624B2
(en)
|
2009-06-02 |
2014-07-22 |
Cyberonics, Inc. |
Processing for multi-channel signals
|
EP2482838A4
(de)
|
2009-09-30 |
2013-04-10 |
Toxcure Inc |
Verwendung von botulinum-neurotoxin zur behandlung von substanzabhängigkeit
|
KR101722290B1
(ko)
|
2009-10-27 |
2017-03-31 |
호라이라 인코포레이티드 |
냉각 가능한 에너지 에미팅 어셈블리를 갖는 전달 장치
|
US8911439B2
(en)
|
2009-11-11 |
2014-12-16 |
Holaira, Inc. |
Non-invasive and minimally invasive denervation methods and systems for performing the same
|
CN102711645B
(zh)
|
2009-11-11 |
2016-12-28 |
赫莱拉公司 |
用于处理组织和控制狭窄的系统和装置
|
JP2011157331A
(ja)
*
|
2010-02-03 |
2011-08-18 |
Chemo-Sero-Therapeutic Research Inst |
高用量投与が可能なボツリヌス毒素製剤
|
US9643019B2
(en)
|
2010-02-12 |
2017-05-09 |
Cyberonics, Inc. |
Neurological monitoring and alerts
|
US8892184B2
(en)
|
2010-10-18 |
2014-11-18 |
Siemens Medical Solutions Usa, Inc. |
Systems and methods for reducing interference in a dual modality imaging system
|
WO2012103224A1
(en)
*
|
2011-01-25 |
2012-08-02 |
Medtronic, Inc. |
Target therapy delivery site selection
|
WO2012174123A1
(en)
|
2011-06-13 |
2012-12-20 |
Allergan, Inc. |
Treatment of psychological trauma
|
US8992941B2
(en)
|
2011-07-08 |
2015-03-31 |
Allergan, Inc. |
Method for treatment of esophageal spasm
|
AU2012282873B2
(en)
|
2011-07-08 |
2016-03-31 |
Allergan, Inc. |
Method for treatment of autonomic nervous system disorders
|
US9144600B2
(en)
|
2011-07-14 |
2015-09-29 |
Allergan, Inc. |
Methods for treatment of incontinence associated with sexual activity
|
EP2734224A1
(de)
|
2011-07-20 |
2014-05-28 |
Allergan, Inc. |
Botulinumtoxin zur verwendung in einem verfahren zur behandlung adipöser ablagerungen
|
US9393291B2
(en)
|
2012-04-12 |
2016-07-19 |
Botulinum Toxin Research Associates, Inc. |
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
|
EP2649984A1
(de)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Verbindungen zur Hemmung neuronaler Exozytose
|
AU2013246882B2
(en)
|
2012-04-13 |
2017-10-19 |
Lubrizol Advanced Materials, Inc. |
Compounds which inhibit neuronal exocytosis (II)
|
EP2649985A1
(de)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Verbindungen zur Hemmung neuronaler Exozytose (III)
|
EP2649983A1
(de)
|
2012-04-13 |
2013-10-16 |
Lipotec, S.A. |
Verbindungen zur Hemmung neuronaler Exozytose (II)
|
US9005628B2
(en)
|
2012-10-04 |
2015-04-14 |
Dublin City University |
Biotherapy for pain
|
US9398933B2
(en)
|
2012-12-27 |
2016-07-26 |
Holaira, Inc. |
Methods for improving drug efficacy including a combination of drug administration and nerve modulation
|
WO2014172372A1
(en)
|
2013-04-15 |
2014-10-23 |
Northwestern University |
Treatment for dopaminergic disorders
|
GB201312317D0
(en)
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
US10149893B2
(en)
|
2013-09-24 |
2018-12-11 |
Allergan, Inc. |
Methods for modifying progression of osteoarthritis
|
US9216210B2
(en)
|
2013-12-23 |
2015-12-22 |
Dublin City University |
Multiprotease therapeutics for chronic pain
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
US9901627B2
(en)
|
2014-07-18 |
2018-02-27 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
US9950194B2
(en)
|
2014-09-09 |
2018-04-24 |
Mevion Medical Systems, Inc. |
Patient positioning system
|
WO2016081767A1
(en)
|
2014-11-19 |
2016-05-26 |
Neurosigma, Inc. |
Trigeminal neurostimulation based upon pulse counting and chronobiology
|
CA2970617C
(en)
|
2014-12-18 |
2021-11-23 |
Dexcel Pharma Technologies Ltd. |
Alternating and semi-alternating poly(ester-anhydride) copolymers
|
RU2733493C2
(ru)
|
2015-01-09 |
2020-10-02 |
Ипсен Байоинновейшн Лимитед |
Катионные нейротоксины
|
GB201517450D0
(en)
|
2015-10-02 |
2015-11-18 |
Ipsen Biopharm Ltd |
Method
|
GB201607901D0
(en)
|
2016-05-05 |
2016-06-22 |
Ipsen Biopharm Ltd |
Chimeric neurotoxins
|
EP3263710A1
(de)
|
2016-07-01 |
2018-01-03 |
Ipsen Biopharm Limited |
Herstellung von aktivierten clostridien-neurotoxinen
|
EP3519430A1
(de)
|
2016-09-29 |
2019-08-07 |
Ipsen Biopharm Limited |
Hybridneurotoxine
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
EP3600438A4
(de)
|
2017-03-29 |
2020-10-28 |
Dexcel Pharma Technologies Ltd. |
Zusammensetzungen mit biologisch abbaubaren copolymeren
|
CN106890196A
(zh)
*
|
2017-04-07 |
2017-06-27 |
青岛东海药业有限公司 |
酪酸梭菌在制备预防或治疗帕金森病制剂中的应用
|
WO2019164852A1
(en)
*
|
2018-02-20 |
2019-08-29 |
Edgewise Therapeutics, Inc. |
Methods and compositions for treating movement disorders
|
CN111465352B
(zh)
|
2018-02-26 |
2024-04-12 |
益普生生物制药有限公司 |
使用超声波引导非细胞毒性蛋白酶的注射
|
GB201812746D0
(en)
|
2018-08-06 |
2018-09-19 |
Gill Steven S |
Method
|
EP3993825A1
(de)
*
|
2019-07-05 |
2022-05-11 |
Allergan, Inc. |
Verfahren zur behandlung und hemmung des fortschreitens von anfällen
|
US10987411B1
(en)
|
2019-10-18 |
2021-04-27 |
Penland Foundation |
Treatment of chronic obstructive pulmonary disease using botulinum toxin
|
US10960060B1
(en)
|
2019-10-18 |
2021-03-30 |
Penland Foundation |
Treatment of cardiac arrhythmia using botulinum toxin
|
US11925677B2
(en)
|
2021-07-12 |
2024-03-12 |
Penland Foundation |
Treatment of diabetes and chronic pancreatitis using botulinum toxin
|
US11738071B2
(en)
|
2021-07-12 |
2023-08-29 |
Penland Foundation |
Treatment of acute and chronic kidney disease
|
WO2021077055A1
(en)
|
2019-10-18 |
2021-04-22 |
Penland Foundation |
Botulinum toxin for use in treatment
|
US11090371B1
(en)
|
2019-10-18 |
2021-08-17 |
Penland Foundation |
Treatment of cirrhosis using botulinum toxin
|
US10967052B1
(en)
|
2019-10-18 |
2021-04-06 |
Penland Foundation |
Treatment of dyslexia using botulinum toxin
|
US10973873B1
(en)
|
2019-10-18 |
2021-04-13 |
Penland Foundation |
Treatment of asthma using botulinum toxin
|
US11241479B2
(en)
|
2019-10-18 |
2022-02-08 |
Penland Foundation |
Treatment methods using botulinum toxins
|
US10960061B1
(en)
|
2019-10-18 |
2021-03-30 |
Penland Foundation |
Treatment of amyotrophic lateral sclerosis using botulinum toxin
|
WO2021137667A1
(ko)
*
|
2019-12-30 |
2021-07-08 |
주식회사 에이티지씨 |
보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
|
CN113832069B
(zh)
*
|
2020-11-30 |
2024-01-30 |
河南农业大学 |
丁酸梭菌及其应用
|
GB202100566D0
(en)
*
|
2021-01-15 |
2021-03-03 |
Ipsen Biopharm Ltd |
Treatment of brain damage
|
GB202103372D0
(en)
|
2021-03-11 |
2021-04-28 |
Ipsen Biopharm Ltd |
Modified clostridial neurotoxins
|
CN113491763B
(zh)
*
|
2021-08-19 |
2023-11-24 |
苏州人本药业有限公司 |
眼镜蛇神经毒素及其制剂在制备预防和/或治疗帕金森病的药物中的应用
|
GB202202719D0
(en)
|
2022-02-28 |
2022-04-13 |
Neurochase Tech Ltd |
Port
|
WO2024069191A1
(en)
|
2022-09-30 |
2024-04-04 |
Ipsen Biopharm Limited |
Clostridial neurotoxin for use in a treatment of bladder pain syndrome
|